Clinical Trial Details

Short Title
Official Title
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patient with CD30-positive mature T-cell lymphomas: the ARROVEN study

Participants in this study have CD-30 positive Mature T-cell Lymphomas (MTCL) that have never been treated. The standard of care for patients with newly diagnosed MTCL is treatment with a combination of drugs called CHOP [cyclophosphamide, hydroxydoxorubicin (also called doxorubicin), vincristine (Oncovin-R), and prednisone].

This study is being done to compare CHOP to a combination of treatment that replaces vincristine with brentuximab vedotin. This combination is called A+CHP [brentuximab vedotin (ADCETRIS-R) plus cyclophosphamide, hydroxydorubicin, and prednisone].

About 300 people will take part in this research study at approximately 90 sites in North America, Europe, and Asia.

Start Date
July 25, 2013
End Date
January 1, 2018
Gender Preference
Age Group
0 - 99 years
Principal Investigator
Lori Rosenstein, MD
Contact Info

Susan Gillen, 319-467-5827

cancer ; CD-30 positive ; IRB#201212504 ; Mature T-cell Lymphomas (MTCL) ; phase 3 ; phase III ; rosenstein ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks